ArticleFrontiers in physiology2012
Plasmacytoid dendritic cells in atherosclerosis.
Article in Frontiers in physiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 44 citations in OpenAlex.
- Emerging insights into inflammation-driven atherosclerosis: immune cell mechanisms.Frontiers in cardiovascular medicine · 2026Review
- Dendritic cells immunotargeted therapy for atherosclerosis.Acta pharmaceutica Sinica. B · 2025Review
- Article
- Immune cell-mediated features of atherosclerosis.Frontiers in cardiovascular medicine · 2024Review
- The role of circulating cell-free DNA as an inflammatory mediator after stroke.Seminars in immunopathology · 2023Review
- Myeloid Cell Diversity and Impact of Metabolic Cues during Atherosclerosis.Immunometabolism · 2020Article
- Dendritic Cells and T Cells, Partners in Atherogenesis and the Translating Road Ahead.Frontiers in immunology · 2020Review
- Recent insights into the implications of metabolism in plasmacytoid dendritic cell innate functions: Potential ways to control these functions.F1000Research · 2017Review
- The anti-inflammatory effects of platelet-derived microparticles in human plasmacytoid dendritic cells involve liver X receptor activation.Haematologica · 2016Article
- Neutrophil extracellular traps: a walk on the wild side of exercise immunology.Sports medicine (Auckland, N.Z.) · 2015Review
- Evaluation of the BDCA2-DTR Transgenic Mouse Model in Chronic and Acute Inflammation.PloS one · 2015Article
- Anti-atherogenic peptide Ep1.B derived from apolipoprotein E induces tolerogenic plasmacytoid dendritic cells.Clinical and experimental immunology · 2014Article
- The dynamic lives of macrophage and dendritic cell subsets in atherosclerosis.Annals of the New York Academy of Sciences · 2014Review
- Plasmacytoid dendritic cells: development, functions, and role in atherosclerotic inflammation.Frontiers in physiology · 2014Review
- Dendritic cells in atherosclerotic inflammation: the complexity of functions and the peculiarities of pathophysiological effects.Frontiers in physiology · 2014Review
- Distinct functions of specialized dendritic cell subsets in atherosclerosis and the road ahead.Scientifica · 2014Review
- Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease.Journal of immunology (Baltimore, Md. : 1950) · 2013Review
- Neuroimmunology of the atherosclerotic plaque: a morphological approach.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis, a chronic inflammatory disease of the vessel wall and the underlying cause of cardiovascular disease, is initiated and maintained by innate and adaptive immunity. Accumulating evidence suggests an important contribution of autoimmune responses to this disease. Plasmacytoid dendritic cells (pDCs), a specialized cell type known to produce large amounts of type I interferons (IFNs) in response to bacterial and viral infections, have recently been revealed to play important roles in atherosclerosis. For example, the development of autoimmune complexes consisting of self-DNA and antimicrobial peptides, which trigger chronic type I IFN production by pDCs, promote early atherosclerotic lesion formation. pDCs and pDC-derived type I IFNs can also induce the maturation of conventional DCs and macrophages, and the development of autoreactive B cells and antibody production. These mechanisms, known to play a role in the pathogenesis of other autoimmune diseases such as systemic lupus erythematosus and psoriasis, may also affect the development and progression of atherosclerotic lesion formation. This review discusses emerging evidence showing a contribution of pDCs in the onset and progression of atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.